DAFTAR PUSTAKA

1. KDIGO (Kidney Disease: Improving Global Outcomes). (2012). KDIGO

Clinical Practice Guidelinefor Anemia in Chronic Kidney Disease.Kidney
International Supplements, 2(4): 288-335.
2. Lerma EV. (2013). Anemia of Chronic Disease and Renal Failure.
http://emedicine.medscape.com/article/1389854-overview.
November 2014].
3. NKUDIC (National

Kidney

and

Urologic

Diseases

[diakses

19

Information

Clearinghouse). (2008). Anemia in Kidney Disease and Dialysis. Bethesda:

National Institutes of Health Publication.
4. National Kidney Foundation. (2001). NKF-KDOQI Clinical Practice
Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J
Kidney Dis, 37(1):182-238.
5. Stevens LA, Coresh J, Greene T,&Levey AS. (2006). AssessingKidney
Function Measuredand Estimated Glomerular Filtration Rate. N Engl J
Med, 354:2473-2483.
6. BC Medical Association & Kidney Foundation of Canada. (2008). Chronic
Kidney Disease Identification, Evaluation and Management of Patients:
Guidelines & Protocols. Vancouver: BC Health Guide.
7. Perhimpunan Nefrologi Indonesia (PERNEFRI). (2011). Pengkajian Status
Besi dan Terapi Besi. Konsensus Manajemen Anemia pada Penyakit Ginjal
Kronik. Ed II.
8. Tong EM& Nissenson AR. (2001). Erythropoietin and Anemia. Semin
Nephrol, 21:190-203.
9. Moore E&Bellomo R. (2011). Erythropoietin (EPO) in Acute Kidney Injury.
Annals of Intensive Care, 1:3-13.
10. Donnelly S. (2001). Why is Erythropoietin Made in the Kidney? The Kidney
Functions as a Critmeter. Am J Kidney Dis, 38:415-425.
11. Tarif N. (2002). Anemia Management in Patients with Chronic Renal
Disease: Current Recommendations. Saudi J Kidney Dis Transplant, 13: 331335.
12. Nurko S. (2006). Anemia in Chronic Kidney Disease: Causes, Diagnosis,
Treatment. Cleveland Clinic Journal pf Medicine, 73: 289-297.
13. Erslev AJ & Besarab A. (1997). Erythropoietin in the Pathogenesis and
Treatment of the Anemia of Chronic Renal Failure. Kidney Int, 51: 622-630.
14. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA,
Caorsi I, Vio CP, Ruiz-Ortega M&Egido J. (2003). Renin-angiotensin System
26

27

Activation

and

Interstitial

Inflammation

in

Human

Diabetic

Nephropathy.Kidney Int,(Suppl): S64-S70.

15. Marsden PA. (2009).Treatment of Anemia in Chronic Kidney Disease
Strategies Based on Evidence. N Engl J Med, 361: 2089-2090.
16. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB&Walker RJ.
(2011). Red Blood Cell Survival in Long-term Dialysis Patients, 58(4):591598.
17. Mehdi U & Toto RD. (2009). Anemia, Diabetes and Chronic Kidney Disease.
Diabetes Care, 32(7): 1320-1326.
18. Stenvinkel P& Alvestrand A. (2002). Inflammation in End-stage Renal
Disease: Sources, Consequences and Therapy. Semin Dial, 15:329-337.
19. Steinvinkel P. (2001). The Role of Inflammation in the Anaemia of End-stage
Renal Disease. Nephrol Dial Transplant, 16(7):36-40.
20. Remuzzi GR& Ingelfinger JR. (2006). Correction of Anemia: Payoffs and
Problems. N Engl J Med,355: 2144-2145.
21. Kalantar Zadeh K, Rodriguez RA& Humphreys MH. (2004). Association
Between Serum Ferritin and Measures of Inflammation, Nutrition and Iron in
Haemodialysis Patients. Nephrol Dial Transplant, 19: 141-149.
22. Nakanishi T& Kuragano T. (2010). Importance of Ferritin for Optimizing
Anemia Therapy in Chronic Kidney Disease. Am J Nephrol, 32: 439-446.
23. Senol E, Ersoy A, et al. (2008). Oxidative Stress and Ferritin Levels in
Haemodialysis Patients. Nephrol Dial Transplant, 23: 665-672.
24. Locatelli F, Aljama P& Barany P. (2004). Revised European Best Practice
Guidelines for the Management of Anaemia in Patients with Chronic Renal
Failure. Nephrol Dial Transplant, 19(Suppl 2): ii1-i47.
25. Bakta IM. (2006). Hematologi Klinik Ringkas. Jakarta: EGC.
26. Weiss G& Goodnough LT. (2005). Anemia of Chronic Disease. N Engl J
Med,352: 1011-1023.
27. Bakhshi S & Besa EC. (2011). Aplastic Anemia. http://emedicine.
medscape.com/article/198759-overview. [diakses tanggal 1 Desember 2013].
28. Fehr T, Ammann P& Garzoni D. (2004). Interpretation of
ErythropoietinLevels in Patients with Various Degrees of Renal Insufficiency
and Anemia.Kidney Int, 66: 1206-1211.
29. Rambod M, Kovesdy CP& Kalantar-Zadeh K. (2008). Combined High
SerumFerritin and Low Iron Saturation in Hemodialysis Patients: the Role
ofInflammation. Clin J Am Soc Nephrol, 3: 1691-1701.
30. Tessitore N, Girelli D& Campostrini N. (2010). Hepcidin is not Useful as
aBiomarker

for

Iron

Needs

in

Haemodialysis

Patients

on

28

MaintenanceErythropoiesis-stimulating Agents. Nephrol Dial Transplant,

25:3996-4002.
31. Drueke TB, Locatelli F& Clyne N. (2006). Normalization of Hemoglobin
Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med,
355(20):2071-2084.
32. Singh AK, Szczech L& Tang KL. (2006). Correction of Anemia with Epoetin
Alfa in Chronic Kidney Disease. N Engl J Med, 355(20):2085-2098.
33. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W& Roger S.
(2004). Darbepoetin Alfa Effectively Treats Anemia in Patients with Chronic
Kidney Disease with De Novo Every-other-week Administration. Am J
Nephrol, 24: 453-460.
34. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W& Brenner R. (2005).
Darbepoetin Alfa Administered Once MonthlyMaintains Hb Concentrations
in Patients with Chronic Kidney Disease. Clin Nephrol, 63: 327-334.
35. Macdougall IC& Cooper AC. (2002). Erythropoietin Resistance: The Role of
Inflammation and Pro-inflammatory Cytokines. Nephrol Dial Transplant,
17:39-43.
36. USRDS System. (2010). USRDS 2010 Annual Data Report: Atlas of Chronic
KidneyDisease and End-Stage Renal Disease in the United States.
NationalInstitutes of Health 2010, National Institute of Diabetes and
Digestiveand Kidney Diseases.
37. Agarwal R. (2010). Individualizing Decision-makingresurrecting the
Doctor-patient Relationship in the Anemia Debate. Clin J Am Soc Nephrol, 5:
1340-1346.
38. Nangaku M. (2006). Chronic Hypoxia and TubulointerstitialInjury: A Final
Common Pathway toEnd-Stage Renal Failure. JASN, 17(1): 17-25.